These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25601471)

  • 1. Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma.
    Dimitrova V; Arcaro A
    Curr Mol Med; 2015; 15(1):82-93. PubMed ID: 25601471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
    Li H; Zeng J; Shen K
    Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
    King D; Yeomanson D; Bryant HE
    J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3 kinase/AKT/mTOR signaling in cancer.
    Sheppard K; Kinross KM; Solomon B; Pearson RB; Phillips WA
    Crit Rev Oncog; 2012; 17(1):69-95. PubMed ID: 22471665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
    Höland K; Salm F; Arcaro A
    Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.
    Rogers HA; Estranero J; Gudka K; Grundy RG
    Oncotarget; 2017 Jan; 8(2):2083-2095. PubMed ID: 27926496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mTOR as a Therapeutic Approach in Medulloblastoma.
    Aldaregia J; Odriozola A; Matheu A; Garcia I
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
    Bartlett JM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
    Pandurangan AK
    Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.
    Corti F; Nichetti F; Raimondi A; Niger M; Prinzi N; Torchio M; Tamborini E; Perrone F; Pruneri G; Di Bartolomeo M; de Braud F; Pusceddu S
    Cancer Treat Rev; 2019 Jan; 72():45-55. PubMed ID: 30476750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.